^
    Back
    Association details:
    Biomarker:FOXP1-ABL1 Fusion
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Br J Haematol
    Title:

    Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia

    Excerpt:
    "In this study, we have investigated two B-ALL patients with acquired chromosomal rearrangements each involving the chromosomal band 9q34 and identified two novel ABL1 fusion genes potentially sensitive to imatinib treatment….FOXP1-ABL1 male/female B-ALL with t(3;9 (p12;q34).... On last follow-up in spring of 2010 she continued in CR, with excellent functionality..."
    DOI:
    10.1111/j.1365-2141.2010.08457